logo

For the Inventor, By the Inventor

Sewell, NJ, United States of America

James S Frazee

This inventor holds 16 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Smithkline Beecham Corporation, Smithkline Beckman Corporation, Smithkline Corporation. Active years: 1976-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James S Frazee. Retrieved from https://idiyas.com/inventor/james-s-frazee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 93.8


Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 123(Granted Patents)


Location History:

  • Collingswood, NJ (US) (1976 - 1989)
  • Sewell, NJ (US) (1988 - 2000)
  • King of Prussia, PA (US) (2005 - 2008)

Company Filing History:

goldMedal9 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal5 out of 207 
 
Smithkline Beckman Corporation
 patents
bronzeMedal2 out of 344 
 
Smithkline Corporation
 patents

Years Active: 1976-2008

Loading Chart...
Loading Chart...
Areas of Expertise:
Dopamine Inhibitors
Peptide Deformylase
Cytokine Antagonists
Amide Compounds
Leukotriene Antagonists
Hydroxamic Acid Derivatives
Ester Prodrugs
Quinolinyl Compounds
Imidazole Derivatives
Pent-4-Ynoic Acids
Mandelamidocephalosporins
16 patents (USPTO):Explore Patents
1. 7365085 - Compounds and methods (2008-04-29),
2. 7323494 - Compounds and methods (2008-01-29),
3. 7247748 - Amide compounds and methods of using the same (2007-07-24),
4. 6967220 - Peptide deformylase inhibitors (2005-11-22),
5. 6037367 - Substituted-pent-4-ynoic acids (2000-03-14),
6. 5665753 - Cytokine inhibiting imidazole substituted hydroxamic acid derivatives (1997-09-09),
7. 5314918 - Leukotriene antagonists (1994-05-24),
8. 5034537 - Leukotriene antagonists (1991-07-23),
9. 4996214 - Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic (1991-02-26),
10. 4992459 - Dopamine-.beta.-hydroxylase inhibitors (1991-02-12),
11. 4863944 - Dopamine-.beta.-hydroxylase inhibitors (1989-09-05),
12. 4772723 - Dopamine .beta.-hydroxylase inhibitors (1988-09-20),
13. 4760089 - Irreversible dopamine-.beta.-hydroxylase inhibitors (1988-07-26),
14. 4743613 - Ester prodrugs of dopamine-.beta.-hydroxylase, inhibitors, composition (1988-05-10),
15. 4532331 - 1-Benzyl-2-aminomethyl imidazole derivatives (1985-07-30),

Title: The Innovative Journey of James S. Frazee

Introduction

James S. Frazee is a notable inventor based in Sewell, NJ (US). He has made significant contributions to the field of innovation, holding a total of 16 patents. His work primarily focuses on compounds and methods that have advanced various applications in science and technology.

Latest Patents

Among his latest patents, Frazee has disclosed compounds with specific formulas that showcase his innovative approach. These compounds and methods are pivotal in enhancing the understanding and application of chemical formulations.

Career Highlights

Frazee has had a distinguished career, working with prominent companies such as SmithKline Beecham Corporation and SmithKline Beckman Corporation. His experience in these organizations has allowed him to develop and refine his inventive skills, contributing to his impressive patent portfolio.

Collaborations

Throughout his career, Frazee has collaborated with notable individuals, including Carl Kaiser and Lawrence I. Kruse. These partnerships have fostered a creative environment that has led to groundbreaking innovations.

Conclusion

James S. Frazee's contributions to the field of invention are marked by his numerous patents and collaborations. His work continues to influence the landscape of scientific innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…